

Title (en)  
A COMBINATION COMPRISING FINGOLIMOD AND AT LEAST ONE ANTI-EPILEPTIC AGENT

Title (de)  
KOMBINATION AUS FINGOLIMOD UND MINDESTENS EINEM ANTIEPILEPTIKUM

Title (fr)  
COMBINAISON COMPRENANT DU FINGOLIMOD ET AU MOINS UN AGENT ANTI-ÉPILEPTIQUE

Publication  
**EP 3810274 A4 20220316 (EN)**

Application  
**EP 19822106 A 20190619**

Priority  
• TR 201808815 A 20180621  
• TR 2019050471 W 20190619

Abstract (en)  
[origin: WO2019245512A2] The present invention relates to a pharmaceutical combination comprising fingolimod or a pharmaceutically acceptable salt thereof and at least one anti-epileptic agent.

IPC 8 full level  
**A61K 31/137** (2006.01); **A61K 9/20** (2006.01); **A61K 9/48** (2006.01); **A61K 31/195** (2006.01); **A61K 31/197** (2006.01); **A61K 31/714** (2006.01); **A61K 45/06** (2006.01); **A61P 25/00** (2006.01); **A61P 25/08** (2006.01); **A61P 25/28** (2006.01); **A61P 37/06** (2006.01)

CPC (source: EP)  
**A61K 31/137** (2013.01); **A61K 31/195** (2013.01); **A61K 31/197** (2013.01); **A61K 31/714** (2013.01); **A61K 45/06** (2013.01); **A61P 25/00** (2017.12); **A61K 9/20** (2013.01); **A61K 9/48** (2013.01)

Citation (search report)  
• [XY] WO 2010051349 A1 20100506 - LEXICON PHARMACEUTICALS INC [US], et al  
• [Y] WO 2013190151 A1 20131227 - SYNTHON BV [NL]  
• [Y] ALICE LARONI ET AL: "Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial", BMC NEUROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 14, no. 1, 1 April 2014 (2014-04-01), pages 65, XP021184467, ISSN: 1471-2377, DOI: 10.1186/1471-2377-14-65  
• See references of WO 2019245512A2

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2019245512 A2 20191226**; **WO 2019245512 A3 20200604**; EP 3810274 A2 20210428; EP 3810274 A4 20220316

DOCDB simple family (application)  
**TR 2019050471 W 20190619**; EP 19822106 A 20190619